Vantage logo

Calithera buys itself a plan B

With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.

Vantage logo

Go or no go? A first for Nefecon

Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.